Edward Lifesciences remains a "Hold" as it trades close to its intrinsic value, despite improved fundamentals and solid third ...
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...
Edwards Lifesciences EW, following the sell-off of the Critical Care wing, looks forward to developing the most comprehensive structural heart portfolio. In TMTT, the robust adoption of the ...
Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, is a company that specializes in innovative products and technologies for structural heart disease and critical care ...
Bernstein analyst Lee Hambright raised the firm’s price target on Edwards Lifesciences (EW) to $74 from $72 and keeps a Market Perform rating on the shares as part of a broader research note ...
US medical device giant Edwards Lifesciences has said patients ... outcomes with rapid recovery and improved quality of life. These data add to the immense body of evidence with multiple years ...
Evercore ISI raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $69 and keeps an In Line rating on the shares. In the firm’s 2025 outlook note for MedTech, Life Science ...
Shares of Edwards Lifesciences Corp. EW shed 0.88% to $70.90 Monday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.61% to ...
In a report released on December 4, Mike Kratky from Leerink Partners maintained a Hold rating on Edwards Lifesciences (EW – Research Report), with a price target of $77.00. Don't Miss our Black ...
Capital Investment Advisors LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.4% during the fourth quarter, according to its most recent disclosure with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback